Malignant Pleural Mesothelioma

Quick Answer

Malignant pleural mesothelioma is usually FDG-avid, and PET/CT contributes to distinguishing malignant from benign pleural disease, staging (especially nodal and distant disease that changes resectability), prognosis (higher metabolic activity → worse outcome), and response assessment. The dominant pitfall is talc pleurodesis: talc provokes an intense chronic granulomatous inflammatory reaction that is markedly FDG-avid and can persist for years, mimicking or masking tumour. Nodularity, rind-like circumferential thickening, and mediastinal pleural involvement favour malignancy; correlation with the CT pattern and the pleurodesis history is essential.

Where FDG helps

Mesothelioma is typically FDG-avid, so PET helps separate malignant from benign pleural thickening, detect nodal and distant metastases that render a patient unresectable, and provide prognostic information (higher SUV/metabolic tumour volume predicts worse survival). It also assesses treatment response, where falling metabolic activity tracks benefit.

Imaging features favouring malignancy on the fused study: nodular pleural thickening, circumferential ("rind") thickening, mediastinal pleural involvement, thickening >1 cm, and interlobar fissure involvement — with corresponding FDG uptake.

The talc-pleurodesis pitfall

Talc pleurodesis — used to control malignant effusions — incites a chronic granulomatous reaction that is intensely and durably FDG-avid (often for years). This can mimic tumour or obscure residual/recurrent disease, and is the classic reason a pleural PET must be read against the procedure history and CT (talc is high-density on CT and often localises the uptake). Do not call FDG-avid pleura malignant without excluding prior pleurodesis.

Common Pitfalls / Cautions

• Talc pleurodesis causes intense, long-lasting FDG uptake — correlate with history and CT density.
• Benign asbestos-related pleural plaques are usually not avid, but inflammation/infection can be.
• Diffuse pleural disease is hard to measure — integrate pattern, not a single SUV.

Board Pearls

• PET/CT's decisive staging role is detecting extrathoracic, contralateral, transdiaphragmatic, and distant metastases that render mesothelioma unresectable — but it is insensitive for early T-stage (chest wall, diaphragm) and understages mediastinal nodes, so it complements rather than replaces MRI and surgical (mediastinoscopy/laparoscopy) staging.
• Epithelioid histology carries the best prognosis and is the subtype generally considered for radical surgery; sarcomatoid/biphasic disease is more aggressive.
• FDG-PET improves biopsy targeting by directing sampling to the most metabolically active pleura, raising diagnostic yield in diffuse disease.
• Whole-body FDG can reveal peritoneal spread and is also used for peritoneal mesothelioma, a distinct primary.

Differential Diagnosis

• Benign asbestos-related pleural disease — plaques (often calcified) and benign fibrothorax; usually low FDG uptake.
• Metastatic pleural carcinomatosis (lung/breast adenocarcinoma, thymic) — mimics mesothelioma on PET; the distinction is histologic/immunohistochemical.
• Infectious/inflammatory pleuritis — empyema, tuberculosis, and prior talc pleurodesis are intensely FDG-avid benign mimics.
• Pleural lymphoma and solitary fibrous tumor of the pleura.
• Peritoneal carcinomatosis versus peritoneal mesothelioma when abdominal disease is present.

Reporting Checklist

• State the CT pattern and any prior pleurodesis/procedure history explicitly before interpreting avid pleura.
• Localize disease affecting resectability — mediastinal/hilar nodes, transdiaphragmatic and peritoneal extension, contralateral pleura, chest wall, and distant metastases — while acknowledging PET understages T and N.
• Report SUVmax / metabolic tumor volume as a baseline and prognostic datum.
• Indicate the most metabolically active site as a biopsy target when tissue is needed.
• For response, integrate the overall pleural pattern rather than a single SUV in diffuse disease.

Self-Check

Key References

• Reviews of FDG-PET/CT in malignant pleural mesothelioma — staging, prognosis, and response.
• Literature on talc pleurodesis as a durable FDG-avid inflammatory pitfall.